Miguel Cid López

Miguel Cid López

Auto-generated profile, based on publicly available information

Miguel Cid López

Affiliations Health Research Institute of Santiago de Compostela (IDIS), Santiago, Spain, Division of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago, Spain, University of Santiago de Compostela, Santiago, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AOAdrián Mosquera Orgueira
Adrián Mosquera Orgueira
ARAndrés Peleteiro Raíndo
Andrés Peleteiro Raíndo
MLMiguel Cid López
Miguel Cid López
BRBeatriz Antelo Rodríguez
Beatriz Antelo Rodríguez
JAJosé Ángel Díaz Arias
José Ángel Díaz Arias
JLJosé Luis Bello López
José Luis Bello López
Background: FLT3 mutation is present in 25–30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously, a variable proportion of wild-type FLT3 patients also responded to these drugs. Methods: We analyzed 6 different transcriptomic datasets of AML cases. Differential expression between mutated and wild-type FLT3 AMLs was performed with the Wilcoxon-rank sum test. Hierarchical clustering was used to identify FLT3-mutation like AMLs. Finally, enrichment in recurrent mutations was performed with the Fisher’s test. Results: A FLT3 mutation-like gene expression pattern was identified among wild-type FLT3 AMLs. This pattern was highly enriched in NPM1 and DNMT3A mutants, and particularly in combined NPM1/DNMT3A mutants. Conclusions: We identified a FLT3 mutation-like gene expression pattern in AML which was highly enriched in NPM1 and DNMT3A mutations. Future analysis about the predictive role of this biomarker among wild-type FLT3 patients treated with FLT3 inhibitors is envisaged.